Recent Articles
Can VEGFR Antibodies Become a Ne...
Th1/Th2 Subset Differentiation: ...
Paired Antibodies for Progestero...
How Do Research‑Grade c‑MET Antibodies Address Bottlenecks in Targeted Biolog...
This article explores basic‑research‑oriented mechanisms for c‑MET‑targeting antibody study, covering HGF‑c‑MET signalling axis, monoclonal antibody limitations, bispecific antibody designs, ADC pre‑research models and biomarker detection workflows. Researchers working on MET...
How Do Research‑Grade c‑MET Antibodies Address Bottlenecks in Targeted Biolog...
This article explores basic‑research‑oriented mechanisms for c‑MET‑targeting antibody study, covering HGF‑c‑MET signalling axis, monoclonal antibody limitations, bispecific antibody designs, ADC pre‑research models and biomarker detection workflows. Researchers working on MET...
Read More
Can Anti‑Tau Antibodies Block Transcellular Tau Pathology Propagation in Alzh...
This article reviews pre‑clinical findings exploring whether anti‑tau antibodies block prion‑like intercellular tau propagation in Alzheimer’s disease model systems. It covers microdialysis measurement of interstitial fluid tau, neuronal activity‑driven tau...
Can Anti‑Tau Antibodies Block Transcellular Tau Pathology Propagation in Alzh...
This article reviews pre‑clinical findings exploring whether anti‑tau antibodies block prion‑like intercellular tau propagation in Alzheimer’s disease model systems. It covers microdialysis measurement of interstitial fluid tau, neuronal activity‑driven tau...
Read More
TRIM21 as a Central Determinant for Anti‑Tau Immunotherapy Efficacy: Mechanis...
This neurodegeneration‑immunology review interprets cytosolic Fc‑receptor TRIM21‑dependent intracellular tau‑aggregate clearance for anti‑tau passive‑immunotherapy, P301S tau‑transgenic / OHSC / hiPSC‑neuron experimental‑model outputs and p‑Tau212 (T212) biomarker‑therapeutic‑target characteristics. It provides phospho‑Tau (T212)...
TRIM21 as a Central Determinant for Anti‑Tau Immunotherapy Efficacy: Mechanis...
This neurodegeneration‑immunology review interprets cytosolic Fc‑receptor TRIM21‑dependent intracellular tau‑aggregate clearance for anti‑tau passive‑immunotherapy, P301S tau‑transgenic / OHSC / hiPSC‑neuron experimental‑model outputs and p‑Tau212 (T212) biomarker‑therapeutic‑target characteristics. It provides phospho‑Tau (T212)...
Read More
Innovative Directions for Modern Biopharma Antibody‑Discovery and Antibody‑En...
This biopharma‑R&D review analyses innovative antibody‑drug development directions covering ADC, multispecific‑antibodies, antibody‑fragments, nanobodies and antibody‑cytokine‑fusion‑proteins. It introduces end‑to‑end industrial‑grade custom antibody‑discovery service from ANT BIO PTE. LTD for target‑validation, lead‑candidate‑screening,...
Innovative Directions for Modern Biopharma Antibody‑Discovery and Antibody‑En...
This biopharma‑R&D review analyses innovative antibody‑drug development directions covering ADC, multispecific‑antibodies, antibody‑fragments, nanobodies and antibody‑cytokine‑fusion‑proteins. It introduces end‑to‑end industrial‑grade custom antibody‑discovery service from ANT BIO PTE. LTD for target‑validation, lead‑candidate‑screening,...
Read More
PTEN Tumour‑Suppressor: Decoding Gene‑Inactivation Mechanisms for Pre‑Clinica...
This oncology‑biology review explains PTEN tumour‑suppressor molecular functions, PI3K‑AKT‑mTOR / MAPK / FAK signalling‑axis regulation, PTEN‑loss‑driven therapeutic‑resistance to immune‑checkpoint‑blockade and pre‑clinical combination‑treatment research. It lists PTEN‑series recombinant rabbit mAbs (S0B2105,...
PTEN Tumour‑Suppressor: Decoding Gene‑Inactivation Mechanisms for Pre‑Clinica...
This oncology‑biology review explains PTEN tumour‑suppressor molecular functions, PI3K‑AKT‑mTOR / MAPK / FAK signalling‑axis regulation, PTEN‑loss‑driven therapeutic‑resistance to immune‑checkpoint‑blockade and pre‑clinical combination‑treatment research. It lists PTEN‑series recombinant rabbit mAbs (S0B2105,...
Read More
Phosphorylated PLCγ1 (Tyr783): Regulating Liquid‑Liquid Phase Separation With...
This adaptive‑immunology signalling review interprets liquid‑liquid phase separation (LLPS) of LAT signalling condensates, dual enzymatic‑scaffold functions of PLCγ1, SH2‑domain‑mediated LAT cross‑linking, CD45‑dephosphorylation shielding and non‑monotonic concentration‑dependent LLPS regulation. It features...
Phosphorylated PLCγ1 (Tyr783): Regulating Liquid‑Liquid Phase Separation With...
This adaptive‑immunology signalling review interprets liquid‑liquid phase separation (LLPS) of LAT signalling condensates, dual enzymatic‑scaffold functions of PLCγ1, SH2‑domain‑mediated LAT cross‑linking, CD45‑dephosphorylation shielding and non‑monotonic concentration‑dependent LLPS regulation. It features...
Read More